Evaluating the benefit of adaptive randomization in the CC-115 arm of the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A phase II randomized Bayesian adaptive platform trial in newly diagnosed MGMT unmethylated glioblastoma.
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Rifaquat Rahman, Lorenzo Trippa, Geoffrey Fell, Eudocia Quant Lee, Isabel Arrillaga-Romany, Mehdi Touat, Jan Drappatz, Evanthia Galanis, Manmeet Singh Ahluwalia, Howard Colman, Louis B. Nabors, Jaroslaw T. Hepel, David Schiff, Mary Roberta Welch, David M. Meredith, E. Antonio Chiocca, David A. Reardon, Keith L. Ligon, Brian Michael Alexander, Patrick Y. Wen
Institutions: Dana-Farber Brigham Cancer Center, Dana-Farber Cancer Institute, Massachusetts General Hospital, Pitié-Salpêtrière Hospital, UPMC Hillman Cancer Center, Mayo Clinic, Cleveland Clinic, University of Utah, Huntsman Cancer Institute, University of Alabama at Birmingham, Tufts Medical Center, University of Virginia, Montefiore Medical Center, Harvard University, Brigham and Women's Hospital, Dana-Farber/Harvard Cancer Center
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3166041191